Direct oral anticoagulants for the treatment of venous thromboembolism in patients with active malignancy: a systematic review and meta-analysis
- 269 Downloads
Low molecular weight heparins (LMWHs) are considered the standard of care for the treatment of venous thromboembolism (VTE) associated with cancer. We conducted a meta-analysis to evaluate the safety and efficacy of direct oral anticoagulants (DOACs) in patients with cancer. We systematically searched Medline for potential randomized-control clinical trials (RCTs) and post-hoc analyses. For each study, data on recurrent VTE, major or clinically relevant non-major bleeding (CRNMB), and major bleeding (MB) were extracted. Initially, a total of 1395 citations were identified. Eight studies met our eligibility criteria. The utilization of DOACs in patients with cancer showed a statistically significant reduction in the risk of VTE recurrence compared to LMWH or warfarin (RR = 0.64; 95% CI 0.46–0.88). Similar rates of major or CRNMB were observed between DOACs and LMWH or warfarin (RR = 1.00; 95% CI 0.75–1.33). There was no significant difference in the rate of MB between DOACs and LMWH or warfarin (RR = 1.31; 95% CI 0.71–2.44). Our results suggest that DOACs might reduce the incidence of VTE recurrence in patients with cancer without putting them at high risk for MB/CRNMB or MB. Our findings were mainly driven by the results of the Hokusai VTE Cancer trial. Given the level of investigated evidence, our findings should be interpreted with caution since the majority of the data were originated from sub-group analyses of large (RCTs). Future studies that are adequately powered are warranted to assess efficacy and safety data of DOACs for the treatment of VTE in patients with different types of cancer.
KeywordsVenous thromboembolism Direct oral anticoagulants Enoxaparin Cancer patients
Compliance with ethical standards
Conflict of interest
The authors have indicated that they have no conflicts of interest regarding the content of this article.
This article does not contain any studies with human participants or animals performed by any authors.
- 13.Raskob GE, van Es N, Segers A, Angchaisuksiri P, Oh D, Boda Z, Lyons RM, Meijer K, Gudz I, Weitz JI (2016) Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematol 3(8):e379–e387CrossRefGoogle Scholar
- 14.Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, Grosso MA, Kakkar AK, Kovacs MJ, Mercuri MF, Meyer G, Segers A, Shi M, Wang TF, Yeo E, Zhang G, Zwicker JI, Weitz JI, Büller HR, Hokusai VTE Cancer Investigators (2018) Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 378:615–624. https://doi.org/10.1056/NEJMoa1711948 CrossRefPubMedGoogle Scholar
- 15.Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P, Christiansen AV, Friedman J, Le Maulf F, Peter N (2014) Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 129:764–772. https://doi.org/10.1161/CIRCULATIONAHA.113.004450 CrossRefPubMedGoogle Scholar
- 16.Eriksson H, Goldhaber SZ, Kakkar A, Kearon C, Schellong SM, Feuring M, Peter N, Friedman J (2013) Influence of active cancer on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis from RE-Cover and RE-Cover II. Blood 122(21):582Google Scholar
- 17.Streiff MB, Milentijevic D, McCrae K, Yannicelli D, Fortier J, Nelson WW, Laliberté F, Crivera C, Lefebvre P, Schein J (2018) Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer. Am J Hematol 93(5):664–671CrossRefPubMedPubMedCentralGoogle Scholar
- 18.Brunetti ND, Gesuete E, De Gennaro L, Correale M, Caldarola P, Gaglione A, Di Biase M (2017) Direct oral anti-coagulants compared with vitamin-K inhibitors and low-molecular-weight-heparin for the prevention of venous thromboembolism in patients with cancer: a meta-analysis study. Int J Cardiol 230:214–221CrossRefPubMedGoogle Scholar
- 23.Prins MH, Lensing AW, Brighton TA, Lyons RM, Rehm J, Trajanovic M, Davidson BL, Beyer-Westendorf J, Pap ÁF, Berkowitz SD (2014) Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematol 1(1):e37–e46CrossRefGoogle Scholar
- 24.Guntupalli S, Brennecke A, Sheeder J, Babayan L, Cheng G, Behbakht K, Corr B, Lefkowits C, Matsuo K, Flink D (2017) A multiinstitutional, prospective randomized open-blinded end-point trial for safety of oral apixaban versus subcutaneous enoxaparin for thromboprophylaxis in women with suspected gynecologic malignancy. Gynecol Oncol 145:221CrossRefGoogle Scholar
- 25.AIO-Studien-gGmbH Rivaroxaban in the treatment of venous thromboembolism (VTE) in cancer patients. https://clinicaltrials.gov/ct2/show/NCT02583191?id=NCT02583191&rank=1&load=cart. Accessed 4 June 2018
- 27.Keita I, Aubin-Auger I, Lalanne C, Aubert J-P, Chassany O, Duracinsky M, Mahé I (2017) Assessment of quality of life, satisfaction with anticoagulation therapy, and adherence to treatment in patients receiving long-course vitamin K antagonists or direct oral anticoagulants for venous thromboembolism. Patient Prefer Adher 11:1625CrossRefGoogle Scholar